Robert B Ford

CHAIRMAN AND CEO

Robert B Ford (CHAIRMAN AND CEO) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in Abbott Laboratories (ABT). Across 1 priced purchase filing, the average 21-session return was +6.5% from execution and +6.3% from disclosure (delay-adjusted; derived). The largest single filing was $46.2M of ABT (398,832 sh across 2 lots, as filed), executed Aug 25.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+6.5%

avg across 1 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+6.3%

same 1 filings, from disclosure

Filings, ttm

1 buys · 1 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$48.2M

shares × price, as filed

Last traded

Aug 25

Filed Aug 27

Median ADV $1.4B across their filed names

Open performance→

Volume by month

Buys $2.0M Sells $83.6M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 2 filings

Sector per market data · by filing · past 12 months

Most traded names

ABT

Abbott Laboratories ABT · 1 buy · 2 sells 3 filings

Recent filings

ABTSALE Abbott Laboratories View filing → $46.2M
398,832 sh across 2 lots
Exec Aug 25
Filed Aug 27 · 5:09 PM ET ABTPURCHASE Abbott Laboratories View filing → $2.0M
18,800 sh × $107.13
Exec Jan 23
Filed Jan 26 · 8:02 AM ET ABTSALE Abbott Laboratories View filing → $37.4M
285,388 sh × $131.17
Exec Feb 5 2025
Filed Feb 7 2025 · 5:30 PM ET ABTSALE Abbott Laboratories View filing → $16.5M
141,679 sh across 2 lots
Exec Sep 12 2024
Filed Sep 13 2024 · 5:30 PM ET